Typically, 15 years are required to develop new drug globally.   Neurotech has been developing Neu2000 and AAD-2004 over the last 8 years and has recently discovered two additional promising compounds. Neurotech has also expanded its drug development capabilities over this period. 

In preparing for competition in the global marketplace, Neurotech  has secured sufficient cash flow for R&D Funding through public listing, employing a conservative business model, and establishing a new drug development infrastructure through the introduction of IT.  

Our partner, Eolith, is a company that specializes in Broadband Convergence Network technology. Neurotech is working with Eolith and large medical center to construct a Ubiquitous Health Monitoring System (UHMS) to select patients with stroke and Alzheimer's and maximize the efficacy of drugs.  Neurotech ultimately seeks to gain entry into the pharmaceutical industry through clinical studies and the marketing of new drugs.

Every Neurotech employee is motivated to succeed and build shareholder value.